X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21726) 21726
Publication (3314) 3314
Book Review (1344) 1344
Book Chapter (59) 59
Conference Proceeding (26) 26
Dissertation (10) 10
Magazine Article (3) 3
Book / eBook (2) 2
Reference (2) 2
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20559) 20559
animals (13186) 13186
humans (12038) 12038
mice (6458) 6458
phosphorylation (6022) 6022
map kinase (5035) 5035
extracellular signal-regulated map kinases - metabolism (4967) 4967
signal transduction (4873) 4873
rats (4682) 4682
cell biology (4614) 4614
male (4558) 4558
map kinase signaling system - drug effects (4464) 4464
biochemistry & molecular biology (4301) 4301
cells, cultured (4143) 4143
apoptosis (3741) 3741
activation (3655) 3655
cell line, tumor (3623) 3623
expression (3469) 3469
enzyme inhibitors - pharmacology (3446) 3446
female (3244) 3244
signal transduction - drug effects (3212) 3212
kinases (3066) 3066
oncology (2985) 2985
proteins (2955) 2955
cell line (2714) 2714
phosphorylation - drug effects (2526) 2526
mitogen-activated protein kinases - metabolism (2471) 2471
neurosciences (2368) 2368
map kinase signaling system (2364) 2364
apoptosis - drug effects (2297) 2297
protein kinase inhibitors - pharmacology (2291) 2291
cancer (2202) 2202
pharmacology & pharmacy (2193) 2193
gene expression (2155) 2155
article (2058) 2058
p38 mitogen-activated protein kinases - metabolism (2049) 2049
map kinase signaling system - physiology (2033) 2033
activated protein-kinase (2006) 2006
extracellular signal-regulated map kinases - antagonists & inhibitors (1962) 1962
cell proliferation - drug effects (1940) 1940
rats, sprague-dawley (1924) 1924
cells (1837) 1837
inflammation (1804) 1804
gene-expression (1789) 1789
research (1776) 1776
extracellular signal-regulated kinase (1755) 1755
enzyme activation (1734) 1734
dose-response relationship, drug (1712) 1712
enzyme activation - drug effects (1690) 1690
research article (1690) 1690
blotting, western (1683) 1683
mitogen-activated protein kinase 1 - metabolism (1677) 1677
proto-oncogene proteins c-akt - metabolism (1650) 1650
analysis (1633) 1633
flavonoids - pharmacology (1629) 1629
inhibition (1623) 1623
protein kinases (1616) 1616
immunology (1523) 1523
cell proliferation (1501) 1501
rodents (1488) 1488
nf-kappa-b (1475) 1475
multidisciplinary sciences (1461) 1461
mitogen-activated protein kinases - antagonists & inhibitors (1446) 1446
in-vitro (1421) 1421
p38 mitogen-activated protein kinases - antagonists & inhibitors (1387) 1387
pathway (1385) 1385
mice, inbred c57bl (1369) 1369
phosphatidylinositol 3-kinases - metabolism (1364) 1364
medicine (1343) 1343
physiological aspects (1342) 1342
physiology (1332) 1332
oxidative stress (1317) 1317
erk (1309) 1309
pyridines - pharmacology (1295) 1295
signal transduction - physiology (1293) 1293
proliferation (1280) 1280
imidazoles - pharmacology (1264) 1264
nf-kappa b - metabolism (1236) 1236
cell survival - drug effects (1224) 1224
mitogen-activated protein kinase 3 - metabolism (1193) 1193
time factors (1190) 1190
in-vivo (1185) 1185
science (1158) 1158
endocrinology & metabolism (1145) 1145
growth (1131) 1131
mutation (1130) 1130
nitriles - pharmacology (1113) 1113
transfection (1088) 1088
rna, messenger - metabolism (1075) 1075
biology (1064) 1064
antineoplastic agents - pharmacology (1057) 1057
protein-kinase (1054) 1054
cytokines (1048) 1048
butadienes - pharmacology (1032) 1032
disease models, animal (1032) 1032
receptor (1032) 1032
health aspects (1010) 1010
signaling (997) 997
phosphatidylinositol 3-kinases - antagonists & inhibitors (984) 984
pathways (983) 983
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21672) 21672
Chinese (54) 54
Russian (11) 11
French (8) 8
Japanese (7) 7
German (4) 4
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation Research, ISSN 0009-7330, 01/2009, Volume 104, Issue 1, pp. 15 - 18
Ischemic postconditioning (IPoC) reduces infarct size following ischemia/reperfusion. Whether or not phosphorylation of RISK (reperfusion injury salvage... 
PERMEABILITY TRANSITION PORE | CARDIAC & CARDIOVASCULAR SYSTEMS | PROTECTION | REPERFUSION | reperfusion injury | NECROSIS-FACTOR-ALPHA | ADENOSINE RECEPTORS | infarct size | INHIBITION | MYOCARDIAL INFARCT SIZE | cardioprotection | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | MOUSE HEARTS | SIGNAL TRANSDUCER | Glycogen Synthase Kinase 3 - physiology | MAP Kinase Kinase 2 - physiology | Nitriles - pharmacology | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Glycogen Synthase Kinase 3 beta | Ribosomal Protein S6 Kinases, 70-kDa - physiology | MAP Kinase Kinase 1 - physiology | Myocardial Reperfusion Injury - enzymology | Ribosomal Protein S6 Kinases, 70-kDa - biosynthesis | Protein Processing, Post-Translational - drug effects | Swine | Mitogen-Activated Protein Kinase 3 - biosynthesis | Myocardial Infarction - pathology | Swine, Miniature | Phosphorylation - drug effects | Myocardial Infarction - enzymology | MAP Kinase Kinase 1 - antagonists & inhibitors | Butadienes - pharmacology | Glycogen Synthase Kinase 3 - biosynthesis | Mitogen-Activated Protein Kinase 1 - physiology | Glycogen Synthase Kinase 3 - antagonists & inhibitors | Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Coronary Occlusion - enzymology | Enzyme Induction | Proto-Oncogene Proteins c-akt - physiology | Enzyme Activation - drug effects | Mitogen-Activated Protein Kinase 3 - physiology | Mitogen-Activated Protein Kinase 1 - biosynthesis | Proto-Oncogene Proteins c-akt - biosynthesis | Animals | Androstadienes - pharmacology | Myocardial Reperfusion | MAP Kinase Kinase 2 - antagonists & inhibitors | Coronary Occlusion - pathology | Phosphatidylinositol 3-Kinases - physiology | Protein Kinase Inhibitors - pharmacology | Myocardial Reperfusion Injury - prevention & control | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Cancer Cell, ISSN 1535-6108, 2010, Volume 17, Issue 6, pp. 547 - 559
In mice, deletion and activation of results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and... 
CELLCYCLE | SIGNALING | EPITHELIAL-MESENCHYMAL TRANSITION | ONCOGENIC K-RAS | CANCER-CELLS | SUPPRESSOR | GENE | ONCOLOGY | SRC | KINASE INHIBITOR | EXPRESSION PROFILES | MUTATIONS | TUMORIGENESIS | Lung Neoplasms - drug therapy | Protein-Serine-Threonine Kinases - deficiency | Protein-Tyrosine Kinases - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Genomics | Humans | Lung Neoplasms - metabolism | Gene Expression Profiling | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Cell Movement - genetics | Phosphorylation - genetics | RNA Interference | Gene Expression Regulation, Neoplastic - genetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - metabolism | Signal Transduction - genetics | Enzyme Inhibitors - therapeutic use | Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors | Focal Adhesion Protein-Tyrosine Kinases - genetics | Focal Adhesions - genetics | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Mice | TOR Serine-Threonine Kinases | src-Family Kinases - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | ras Proteins - genetics | Lung Neoplasms - pathology | Cell Transdifferentiation - genetics | Protein-Tyrosine Kinases - genetics | Neoplasm Metastasis - drug therapy | Mice, Mutant Strains | Protein-Serine-Threonine Kinases - antagonists & inhibitors | src-Family Kinases - metabolism | Female | Drug Therapy, Combination | Lung Neoplasms - genetics | Cell Adhesion - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Focal Adhesion Protein-Tyrosine Kinases - metabolism | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | src-Family Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - genetics | Proto-Oncogene Proteins - genetics | Up-Regulation - genetics | Xenograft Model Antitumor Assays | Neoplasm Metastasis - genetics | Animals | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Focal Adhesions - metabolism | Proteomics | Protein Kinase Inhibitors - pharmacology | Oncology, Experimental | Analysis | Lung cancer | Development and progression | Metastasis | Research | Cancer | Index Medicus
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 02/2005, Volume 288, Issue 2, pp. 971 - 976
Pharmacological activation of the prosurvival kinases Akt and ERK-1/2 at reperfusion, after a period of lethal ischemia, protects the heart against... 
Myocardial infarction | Phosphatidylinositol 3-kinase-Akt | Reperfusion injury | Mitogen-activated protein kinases | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | phosphatidylinositol 3-kinase-Akt | HEARTS | myocardial infarction | INJURY | reperfusion injury | MITOCHONDRIAL PERMEABILITY TRANSITION | mitogen-activated protein kinases | PORE | PERIPHERAL VASCULAR DISEASE | RADICALS | Phosphorylation | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Male | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Myocardial Reperfusion Injury - pathology | Myocardial Infarction - pathology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Survival - physiology | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Proto-Oncogene Proteins - antagonists & inhibitors | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | MAP Kinase Kinase 1 - metabolism | Myocardium - pathology | MAP Kinase Kinase 2 - metabolism | Myocardial Infarction - metabolism | Rats, Sprague-Dawley | Proto-Oncogene Proteins c-akt | Myocardial Reperfusion Injury - metabolism | Myocardium - enzymology | Animals | Mitogen-Activated Protein Kinase 3 - metabolism | Ischemic Preconditioning, Myocardial | MAP Kinase Kinase 2 - antagonists & inhibitors | Mitogen-Activated Protein Kinase 1 - metabolism | Index Medicus
Journal Article
Nature Structural & Molecular Biology, ISSN 1545-9993, 12/2004, Volume 11, Issue 12, pp. 1192 - 1197
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 13, pp. 2139 - 2146
Purpose To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogenactivated protein kinase kinase (MEK) 1/2 inhibitor... 
MEK INHIBITOR | POTENT | VIVO | ONCOLOGY | PATHWAY | GROWTH | COLON | TUMORS | ras Proteins - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Extracellular Signal-Regulated MAP Kinases - metabolism | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Benzimidazoles - administration & dosage | Neoplasms - genetics | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Benzimidazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Leukocytes, Mononuclear - drug effects | Drug Administration Schedule | Administration, Oral | Benzimidazoles - pharmacokinetics | Neoplasms - enzymology | MAP Kinase Kinase 1 - metabolism | Proto-Oncogene Proteins - genetics | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Ki-67 Antigen - analysis | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Leukocytes, Mononuclear - enzymology | Aged | Cell Proliferation - drug effects | Mutation | Neoplasm Staging | Neoplasms - pathology | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 5/2006, Volume 103, Issue 18, pp. 7136 - 7141
Sustained activation of poly(ADP-ribose) polymerase-1 (PARP-1) and extracellular signal-regulated kinases 1/2 (ERK1/2) both promote neuronal death. Here we... 
Cell culture techniques | Phosphorylation | Neurons | Astrocytes | Cell death | DNA damage | Small interfering RNA | Gene expression regulation | Hypoglycemia | Down regulation | APOPTOSIS | ACTIVATED PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | FOCAL CEREBRAL-ISCHEMIA | DNA-DAMAGE | neuron | MAP KINASES | CELL-DEATH | mitogen-activated protein kinase | INHIBITION | hypoglycemia | CORTICAL NEURON CULTURES | BRAIN INJURY | astrocyte | ERK | RNA, Small Interfering - genetics | MAP Kinase Signaling System - physiology | Humans | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Neurons - cytology | Hypoglycemia - pathology | MAP Kinase Kinase 1 - genetics | Mitogen-Activated Protein Kinase 1 - genetics | Cell Death | Neurons - metabolism | MAP Kinase Kinase 2 - genetics | Fibroblasts - metabolism | Recombinant Proteins - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Mitogen-Activated Protein Kinase 3 - genetics | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Cells, Cultured | Rats | MAP Kinase Kinase 1 - metabolism | MAP Kinase Kinase 2 - metabolism | Recombinant Proteins - genetics | Hypoglycemia - metabolism | Poly(ADP-ribose) Polymerases - metabolism | Animals | Poly(ADP-ribose) Polymerases - genetics | Mitogen-Activated Protein Kinase 3 - metabolism | MAP Kinase Kinase 2 - antagonists & inhibitors | Fibroblasts - cytology | Mice | Enzyme Activation | Poly (ADP-Ribose) Polymerase-1 | Mitogen-Activated Protein Kinase 1 - metabolism | RNA, Small Interfering - metabolism | Research | Protein kinases | Neurology | Signal transduction | Enzymes | Inhibitor drugs | Index Medicus | Biological Sciences
Journal Article
Nature Genetics, ISSN 1061-4036, 2012, Volume 44, Issue 2, pp. 133 - 139
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 2, pp. 107 - 114
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Science Signaling, ISSN 1945-0877, 03/2011, Volume 4, Issue 166, pp. ra17 - ra17
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 18, pp. 3936 - 3944
Abstract Background Ovarian cancer is the major cause of death from gynaecological malignancy with a 5 year survival of only ∼30% due to resistance to platinum... 
Hematology, Oncology and Palliative Medicine | PI3Kinase | RAS/ERK pathway | Therapeutics | Ovarian cancer | KINASE PATHWAY | SENSITIVITY | ANTITUMOR-ACTIVITY | MEK INHIBITORS | BREAST-CANCER | LUNG-CANCER | MUTATION STATUS | THERAPY | PI3K | ONCOLOGY | KRAS | ras Proteins - genetics | Diphenylamine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Humans | Ovarian Neoplasms - pathology | ras Proteins - metabolism | Immunoblotting | Gene Expression Profiling | Phosphatidylinositol 3-Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - genetics | MAP Kinase Kinase 1 - genetics | Ovarian Neoplasms - genetics | TOR Serine-Threonine Kinases - antagonists & inhibitors | Diphenylamine - analogs & derivatives | Pyridones - administration & dosage | Benzamides - administration & dosage | TOR Serine-Threonine Kinases - genetics | Female | Benzamides - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Diphenylamine - administration & dosage | MAP Kinase Kinase 2 - genetics | Ovarian Neoplasms - drug therapy | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyrimidines - administration & dosage | MAP Kinase Kinase 1 - metabolism | MAP Kinase Kinase 2 - metabolism | Signal Transduction - genetics | Pyrimidines - pharmacology | Reverse Transcriptase Polymerase Chain Reaction